- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT00907153
Vitamin D for the Treatment of Women With Polycystic Ovary Syndrome (PCOS)
Vitamin D Supplementation in Polycystic Ovary Syndrome: a Randomized Controlled Trial.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
As many cells throughout the body possess the vitamin D receptor, adequate vitamin D levels may be essential for multiple physiologic functions. In recent years, vitamin D insufficiency has been linked to insulin resistance, inflammation, poor psychological health, obesity, type 2 diabetes, and cardiovascular disease - these are also commonly found in women with Polycystic Ovary syndrome (PCOS). We believe that vitamin D insufficiency contributes to insulin resistance, inflammation, and psychological distress in women with PCOS. These adverse effects may ultimately increase the risk for serious long-term complications in PCOS, including type 2 diabetes and cardiovascular disease. The key objectives of this research study are to determine the effects of vitamin D supplementation on insulin resistance, inflammation, mood and overall well-being in women with PCOS.
The protocol has been modified by adding the following specific aim: To compare vascular function in healthy age and BMI similar matched women to PCOS women pre-treatment. Our hypothesis is that PCOS women will have greater attenuations in retinal vascular reactivity compared to healthy control women, demonstrating poorer endothelial function. We are currently recruiting healthy women who are age and BMI similar to the PCOS women and measure their retinal vascular reactivity for comparisons to the PCOS women's pre-treatment vascular reactivity. These healthy women will only have a baseline visit in which retinal vascular reactivity will be measured. They will not be enrolled in the placebo or Vitamin D randomization process as described above.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
- Faza 1
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stany Zjednoczone, 17033
- Penn State College of Medicine, Penn State Milton S Hershey Medical Center
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
Diagnosis of PCOS based on:
- Eight or fewer menstrual periods per year or spontaneous intermenstrual periods of greater than or equal to 45 days, and
- Elevated testosterone levels
Exclusion Criteria:
- Current Pregnancy or Nursing
- Elevated calcium
- Kidney Stones or kidney disease
- Current use of vitamin D (other than a multivitamin)
- Use of metformin or other insulin sensitizing drugs in the last 3 months
- Elevated prolactin or untreated thyroid disease
- Diabetes, Liver disease, Heart disease, or other serious medical condition
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Komparator placebo: Placebo
|
Placebo by mouth once daily for 12 weeks
|
Eksperymentalny: Witamina D
|
Vitamin D 300 mcg by mouth once daily for 12 weeks
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Mean Quantitative Insulin Sensitivity Check Index (QUICKI)
Ramy czasowe: Baseline and 12 weeks
|
Quantitative insulin sensitivity check index (QUICKI) is a validated measure of insulin sensitivity based on fasting insulin and glucose.
Quantitative insulin sensitivity check index (QUICKI) = 1/[log(I(0)) + log(G(0))]).
|
Baseline and 12 weeks
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Mean High Sensitive C-reactive Protein (hsCRP)
Ramy czasowe: Baseline and 12 weeks
|
High sensitive C-reactive protein (hsCRP) was assessed as a measure of inflammation.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Systolic Blood Pressure
Ramy czasowe: Baseline and 12 weeks
|
Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Diastolic Blood Pressure
Ramy czasowe: Baseline and 12 weeks
|
Blood pressure was measured in the right arm in the sitting position after a 15-minute rest.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Fasting Glucose
Ramy czasowe: Baseline and 12 weeks
|
Glucose was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Fasting Insulin
Ramy czasowe: Baseline and 12 weeks
|
Insulin was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean 2-hour Glucose
Ramy czasowe: Baseline and 12 weeks
|
Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).
|
Baseline and 12 weeks
|
Change From Baseline in Mean 2-hour Insulin
Ramy czasowe: Baseline and 12 weeks
|
Participants underwent a 75-gram oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 2 hours and used to calculate the insulin sensitivity index (ISI 0,120).
|
Baseline and 12 weeks
|
Change From Baseline in Mean Insulin Sensitivity Index (ISI 0,120)
Ramy czasowe: Baseline and 12 weeks
|
Participants underwent a 75-g oral glucose tolerance test, in which blood samples for glucose and insulin were obtained at 0 and 120 minutes and used to calculate the insulin sensitivity index (ISI0,120).
The ISI 0,120 = the glucose uptake rate divided by the mean plasma glucose divided by the log(mean serum insulin).
|
Baseline and 12 weeks
|
Change From Baseline in Mean Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Ramy czasowe: Baseline and 12 weeks
|
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) is a validated measure of insulin resistance based on fasting insulin and glucose.
HOMA-IR is calculated as the product of fasting glucose and insulin divided by 22.5.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Total Cholesterol
Ramy czasowe: Baseline and 12 weeks
|
Lipid profile was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean HDL Cholesterol
Ramy czasowe: Baseline and 12 weeks
|
Lipid profile was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean LDL Cholesterol
Ramy czasowe: Baseline and 12 weeks
|
Lipid profile was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Triglycerides
Ramy czasowe: Baseline and 12 weeks
|
Lipid profile was assessed after 12 hours of fasting.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Total Testosterone
Ramy czasowe: Baseline and 12 weeks
|
Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Free Testosterone
Ramy czasowe: Baseline and 12 weeks
|
Total and free testosterone levels were assessed from blood samples to evaluate effects on hyperandrogenemia in PCOS.
|
Baseline and 12 weeks
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Mean 25-hydroxyvitamin D
Ramy czasowe: Baseline and 12 weeks
|
Total 25-hydroxyvitamin D was assayed by the Immunodiagnostic Systems radioimmunoassay.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Vitamin D Binding Protein
Ramy czasowe: Baseline and 12 weeks
|
Vitamin D binding protein levels were assessed as it has been linked with insulin resistance and type 2 diabetes.
|
Baseline and 12 weeks
|
Change From Baseline in Mean Intact Parathyroid Hormone (i-PTH)
Ramy czasowe: Baseline and 12 weeks
|
Intact parathyroid hormone levels were assessed as they have been linked with obesity and insulin resistance.
|
Baseline and 12 weeks
|
Współpracownicy i badacze
Sponsor
Śledczy
- Główny śledczy: Nazia Raja-Khan, M.D., Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 29714
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Zespół policystycznych jajników
-
Centre Hospitalier Universitaire DijonNovartis PharmaceuticalsRekrutacyjnyMegalencephaly-włośniczkowy zespół polimikrogyrii (MCAP)Francja
Badania kliniczne na Vitamin D
-
Johns Hopkins UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)ZakończonyNiedokrwistość w przewlekłej chorobie nerekStany Zjednoczone
-
Rhode Island HospitalVirtually Better, Inc.ZakończonyZdrowie psychiczne | Ludzki wirus niedoboru odpornościStany Zjednoczone
-
Royal Prince Alfred Hospital, Sydney, AustraliaZakończony
-
GlaxoSmithKlineZakończonyGrypa, człowiekStany Zjednoczone, Belgia
-
Lee's Pharmaceutical LimitedNieznanyRak nabłonka jajnika | Rak jajowodu | Pierwotny rak otrzewnejChiny
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Rekrutacyjny
-
University of AarhusNovo Nordisk A/S; Aarhus University Hospital; AP Moeller Foundation; Danish Diabetes...RekrutacyjnyStarzenie się | Zaburzenia metabolizmu | Ketonemia | Zaburzenia mięśnioweDania
-
University Medical Center GroningenMaastricht University Medical Center; UMC Utrecht; Academisch Medisch Centrum... i inni współpracownicyZakończony
-
Daewoong Pharmaceutical Co. LTD.Jeszcze nie rekrutacja
-
Abbott Medical DevicesZakończonyNiewydolność sercaStany Zjednoczone